Skip to main navigation Skip to search Skip to main content

A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-α fusion protein in chronic hepatitis C patients who have failed previous interferon-α-based therapy

  • Vijayan Balan
  • , David R. Nelson
  • , Mark S. Sulkowski
  • , Gregory T. Everson
  • , Louis R. Lambiase
  • , Rusell H. Wiesner
  • , Rolland C. Dickson
  • , Anthony B. Post
  • , Robert R. Redfield
  • , Gary L. Davis
  • , Avidan U. Neumann
  • , Blaire L. Osborn
  • , William W. Freimuth
  • , G. Mani Subramanian
  • Mayo Clinic Scottsdale, AZ
  • University of Florida
  • Johns Hopkins University
  • University of Colorado Denver
  • Mayo Clinic Rochester, MN
  • Mayo Clinic Jacksonville, FL
  • Case Western Reserve University
  • University of Maryland, College Park
  • Baylor Health Care System
  • GlaxoSmithKline

Research output: Contribution to journal › Article › peer-review

67 Scopus citations

Fingerprint

Dive into the research topics of 'A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-α fusion protein in chronic hepatitis C patients who have failed previous interferon-α-based therapy'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science